The FDA has "repeatedly stated that effectiveness against transmission remains unproven," the trio write, noting that the agency’s website maintains: "the scientific community does not yet know if Comirnaty will reduce such transmission."
The US Food and Drug Administration (FDA) has recently announced an initiative where they are inviting people to report “misinformation” regarding health topics online.
"Our meta-analysis highlights a link between SARS-CoV-2 vaccination and new onset or worsening of inflammatory and autoimmune skin diseases," the study authors write.
The ruling mandates that the FDA, which initially proposed a release timeline of approximately 23.5 years, must now disclose all relevant documents by mid-2025.
The FDA analysts also raised concerns about whether women with medical conditions that should preclude them from taking the pill, primarily breast cancer and undiagnosed vaginal bleeding, would avoid the product.